Literature DB >> 33911167

Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease.

Mi Na Kim1,2, Kyungdo Han3, Juhwan Yoo4, Yeonjung Ha5, Young Eun Chon5, Ju Ho Lee5, Tracey G Simon6,7,8, Andrew T Chan6,7, Seong Gyu Hwang9.   

Abstract

We investigated the association between body weight variability and the risks of cardiovascular disease and mortality in patients with nonalcoholic fatty liver disease (NAFLD) using large-scale, nationwide cohort data. We included 726,736 individuals with NAFLD who underwent a health examination between 2009 and 2010. NAFLD was defined as a fatty liver index ≥ 60, after excluding significant alcohol intake, viral hepatitis, and liver cirrhosis. Body weight variability was assessed using four indices, including variability independent of the mean (VIM). During a median 8.1-year follow-up, we documented 11,358, 14,714, and 22,164 cases of myocardial infarction (MI), stroke, and all-cause mortality, respectively. Body weight variability was associated with an increased risk of MI, stroke, and mortality after adjusting for confounding variables. The hazard ratios (HRs) (95% confidence intervals) for the highest quartile, compared with the lowest quartile, of VIM for body weight were 1.15 (1.10-1.20), 1.22 (1.18-1.26), and 1.56 (1.53-1.62) for MI, stroke, and all-cause mortality, respectively. Body weight variability was associated with increased risks of MI, stroke, and all-cause mortality in NAFLD patients. Appropriate interventions to maintain a stable weight could positively affect health outcomes in NAFLD patients.

Entities:  

Year:  2021        PMID: 33911167     DOI: 10.1038/s41598-021-88733-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  51 in total

Review 1.  NAFLD: a multisystem disease.

Authors:  Christopher D Byrne; Giovanni Targher
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 3.  Nonalcoholic Fatty Liver Disease and Obesity Treatment.

Authors:  Katherine T Brunner; Cameron J Henneberg; Robert M Wilechansky; Michelle T Long
Journal:  Curr Obes Rep       Date:  2019-09

4.  Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients.

Authors:  Chunlong Li; Panpan Guo; Akinkunmi Paul Okekunle; Xiaoning Ji; Min Huang; Jiayue Qi; Yongshuai Jiang; Rennan Feng; Rui Li
Journal:  J Gastroenterol Hepatol       Date:  2018-07-16       Impact factor: 4.029

5.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

Authors:  Eduardo Vilar-Gomez; Yadina Martinez-Perez; Luis Calzadilla-Bertot; Ana Torres-Gonzalez; Bienvenido Gra-Oramas; Licet Gonzalez-Fabian; Scott L Friedman; Moises Diago; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2015-04-10       Impact factor: 22.682

Review 6.  Nonalcoholic Steatohepatitis: A Review.

Authors:  Adam C Sheka; Oyedele Adeyi; Julie Thompson; Bilal Hameed; Peter A Crawford; Sayeed Ikramuddin
Journal:  JAMA       Date:  2020-03-24       Impact factor: 56.272

7.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.

Authors:  Giovanni Targher; Christopher D Byrne; Amedeo Lonardo; Giacomo Zoppini; Corrado Barbui
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

8.  Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT.

Authors:  Linda Penn; Martin White; Jaana Lindström; Annemieke Th den Boer; Ellen Blaak; Johan G Eriksson; Edith Feskens; Pirjo Ilanne-Parikka; Sirkka M Keinänen-Kiukaanniemi; Mark Walker; John C Mathers; Matti Uusitupa; Jaakko Tuomilehto
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

Review 9.  Recent research trends and updates on nonalcoholic fatty liver disease.

Authors:  Jeong-Ju Yoo; Won Kim; Moon Young Kim; Dae Won Jun; Sang Gyune Kim; Jong-Eun Yeon; Jin Woo Lee; Yong Kyun Cho; Sang Hoon Park; Joo Hyun Sohn
Journal:  Clin Mol Hepatol       Date:  2018-08-08
View more
  2 in total

1.  Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome.

Authors:  Punyisa Boonchai; Chayanis Kositamongkol; Suchanart Jitrukthai; Sukumal Phothirat; Euarat Mepramoon; Pongpol Nimitpunya; Weerachai Srivanichakorn; Thanet Chaisathaphol; Chaiwat Washirasaksiri; Chonticha Auesomwang; Tullaya Sitasuwan; Rungsima Tinmanee; Naruemit Sayabovorn; Phunchai Charatcharoenwitthaya; Pochamana Phisalprapa
Journal:  J Clin Med       Date:  2022-04-26       Impact factor: 4.964

2.  Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome.

Authors:  Suchanart Jitrukthai; Chayanis Kositamongkol; Punyisa Boonchai; Euarat Mepramoon; Pinyapat Ariyakunaphan; Pongpol Nimitpunya; Weerachai Srivanichakorn; Thanet Chaisathaphol; Chaiwat Washirasaksiri; Chonticha Auesomwang; Tullaya Sitasuwan; Rungsima Tinmanee; Naruemit Sayabovorn; Phunchai Charatcharoenwitthaya; Pochamana Phisalprapa
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.